宁波美诺华药业股份有限公司关于2021年股票期权与限制性股票激励计划首次授予第三个行权期自主行权结果暨股份变动公告

Group 1 - The core point of the announcement is the third exercise period of the stock option and restricted stock incentive plan, allowing for the exercise of 1,976,997 stock options from January 17, 2025, to December 29, 2025, with 518,448 shares exercised by the end of the period, accounting for 26.22% of the total exercisable amount [2][23][21] - The decision-making process for the stock option exercise was approved by the board of directors and the supervisory board on November 18, 2021, with independent directors providing their consent [3][6] - The company has adjusted the number of incentive participants from 327 to 302 due to voluntary withdrawals, maintaining the total stock options at 3,865,060 and restricted stocks at 1,734,940 [7][8] Group 2 - The stock options exercised will be listed for trading on the second trading day after the exercise date, with the first trading day being January 17, 2025 [23] - The total funds raised from the exercised shares amount to 11,779,138.56 yuan, with the stock options being issued as ordinary shares [26] - The company confirms that the exercise of stock options will not have a significant impact on its financial status or operational results [27] Group 3 - The company plans to use idle raised funds for cash management, amounting to 10 million yuan, to enhance the efficiency of fund utilization [31][32] - The funds for cash management will come from idle convertible bond proceeds, which totaled 520 million yuan, netting 512.7 million yuan after expenses [33] - The cash management will not affect the implementation of investment projects and is expected to improve the returns on idle funds [34][38]